Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Rare human antibodies protect mice from lethal strains of influenza

Scientists have identified a new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work was conducted by researchers at Theraclone Sciences, with collaborators at University of Wisconsin-Madison, University of Tokyo and Johns Hopkins University; and is reported this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

29 Jun 2010

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

The International AIDS Vaccine Initiative (IAVI) announced today that the Government of Japan pledged a US$10 million grant to support AIDS vaccine research and development over the next five years. The grant, which will be channeled through a newly established World Bank trust fund, is the first of its kind from the Japanese government to IAVI.

28 Jun 2010

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

Sixth annual Mayors Campaign Against HIV launched to encourage people test for HIV

OraSure Technologies, Inc. and the National Association of People with AIDS announced today the launch of the sixth annual Mayors Campaign Against HIV, a national campaign to encourage testing for HIV and promote the benefits of knowing one's HIV status. The Campaign is part of the annual observance of National HIV Testing Day on Sunday, June 27, 2010.

25 Jun 2010

IDRI signs Research Collaboration Agreement with PATH

Two global health non-profit organizations headquartered in Seattle, Washington, the Infectious Disease Research Institute and PATH, have entered into a Research Collaboration Agreement to evaluate novel adjuvants for their ability to enhance the immune response of pandemic influenza vaccines in development. The collaboration supports the goal of PATH's influenza vaccine project to advance the development of promising new influenza vaccines focusing on novel technologies that can be accessible, affordable, and available to people in low-resource countries in a global outbreak.

25 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

Walgreen third-quarter sales up 6.1% to record $17.2 billion

Walgreens today announced earnings and sales results for the third quarter of fiscal year 2010.

22 Jun 2010

BD, PEPFAR commence multi-year initiative to improve blood collection practices in African clinics, hospitals

BD (Becton, Dickinson and Company), a leading global medical technology company, and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC) today set in motion a joint, multi-year initiative to improve blood collection practices in African clinics and hospitals.

From BD (Becton, Dickinson and Company) 22 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Recent releases in Global Health

The U.N.'s plan to improve maternal health is lacking "the one element that will make it work. Human rights," according to blog post on Huffington Post. "Medical causes of maternal death - hemorrhage, sepsis, hypertension, unsafe abortion, HIV and AIDS - are inextricably linked to human rights. Each one of these instances can be prevented or treated by simply respecting women's human rights in health policies and delivery of services, and addressing systemic gender inequality."

19 Jun 2010

2009 H1N1 pandemic influenza vaccine protects against 1918 influenza virus: Report

Mice injected with a 2009 H1N1 pandemic influenza vaccine and then exposed to high levels of the virus responsible for the 1918 influenza pandemic do not get sick or die, report scientists funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

17 Jun 2010

InGenesis president named finalist in business services category of Ernst & Young Entrepreneur Of The Year awards

Veronica Edwards, president and CEO of InGenesis, Inc., is the only San Antonio finalist in the business services category of the Ernst & Young Entrepreneur Of The Year awards for the Houston and Gulf Coast Area. Ernst & Young LLP recently announced 36 area finalists selected by a panel of independent judges.

17 Jun 2010

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

A team of molecular biologists and computer scientists at Stony Brook University have used a novel method to weaken (attenuate) influenza virus by way of designing hundreds of mutations to its genetic code to create an effective vaccine. Reported online and in the July issue of Nature Biotechnology, the method may be a major step in developing more effective and safe vaccines against influenza, which claims 250,000 to 500,000 lives annually worldwide, partly because existing vaccines are not fully effective.

17 Jun 2010

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Flu vaccine delivered through skin patches containing microneedles has proven at least as effective at preventing influenza in mice as intramuscular, hypodermic flu immunization.

16 Jun 2010

Vaccination against 2009 H1N1 influenza virus may also protect against 1918 Spanish influenza virus

Researchers at Mount Sinai School of Medicine have determined people who were vaccinated against the 2009 H1N1 influenza virus may also be protected against the lethal 1918 Spanish influenza virus, which killed more than 50 million people worldwide. The new findings are published in the current issue of Nature Communications.

16 Jun 2010

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Acclaimed virologist Robert Webster, Ph.D., of St. Jude Children's Research Hospital, presented the 2010 Leeuwenhoek prize lecture today, a prestigious recognition awarded by the Royal Society in London.

16 Jun 2010

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

11 Jun 2010

Pandemic News and Research

Further Reading

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Rare human antibodies protect mice from lethal strains of influenza

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Sixth annual Mayors Campaign Against HIV launched to encourage people test for HIV

IDRI signs Research Collaboration Agreement with PATH

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Walgreen third-quarter sales up 6.1% to record $17.2 billion

BD, PEPFAR commence multi-year initiative to improve blood collection practices in African clinics, hospitals

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Recent releases in Global Health

2009 H1N1 pandemic influenza vaccine protects against 1918 influenza virus: Report

InGenesis president named finalist in business services category of Ernst & Young Entrepreneur Of The Year awards

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Vaccination against 2009 H1N1 influenza virus may also protect against 1918 Spanish influenza virus

Acclaimed virologist delivers the 2010 Leeuwenhoek prize lecture

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Investment report on Novavax

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News